| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/11/2002 | WO2000052048A9 Modulators of beta-amyloid peptide aggregation comprising d-amino acids |
| 04/11/2002 | WO2000047762A9 Enriched central nervous system cell populations |
| 04/11/2002 | US20020042517 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| 04/11/2002 | US20020042513 Therapeutic compounds |
| 04/11/2002 | US20020042512 Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| 04/11/2002 | US20020042443 Estrogen agonist / antagonist metabolites |
| 04/11/2002 | US20020042435 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/11/2002 | US20020042434 Pharmaceutical composition |
| 04/11/2002 | US20020042427 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 04/11/2002 | US20020042426 Novel basic derivatives of benz[e] isoindol-1-ones and pyrrolo[3,4-c] quinolin-1ones with 5-HT3-antagonistic activity, their preparation and their therapeutic use |
| 04/11/2002 | US20020042421 Antiinflammatory agents |
| 04/11/2002 | US20020042416 6-azauracil derivatives as IL-5 inhibitors |
| 04/11/2002 | US20020042415 Dipeptide derivatives |
| 04/11/2002 | US20020042413 Central nervous system disorders; cognition activators |
| 04/11/2002 | US20020042412 Fused azepinone cyclin dependent kinase inhibitors |
| 04/11/2002 | US20020042405 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 04/11/2002 | US20020042400 Antihistamines |
| 04/11/2002 | US20020042397 4-hydroxycinnoline-3-carboxyamides as antiviral agents |
| 04/11/2002 | US20020042390 Therapy for central nervous system disorders; administeringnucleoside |
| 04/11/2002 | US20020042385 Cloning of a novel 7TM receptor AXOR-2 |
| 04/11/2002 | US20020042380 Topical application of ascorbic acid compounds for augmenting the synthesis of epidermal ceramides |
| 04/11/2002 | US20020042376 Antiinflammatory agents; autoimmune disease; antiischemic agents |
| 04/11/2002 | US20020042373 Administering thrombin receptor antagonist; bone disorders |
| 04/11/2002 | US20020042372 Genetic engineering; central nervous system disorders |
| 04/11/2002 | US20020042368 Integrin antagonists |
| 04/11/2002 | US20020042357 Polypharmacophoric agents |
| 04/11/2002 | US20020042144 Preventing agglomeration of bodily fluid; obtain body fluid sample, incubate with enzyme inhibitors, monitor body fluid agglomeration |
| 04/11/2002 | US20020042114 Novel human protein kinases |
| 04/11/2002 | US20020042103 Process for the preparation of pseudomonic acid a antibiotic by microbiological method |
| 04/11/2002 | US20020042101 Nucleotide sequences which code enzymatic polypeptide for use in the treatment of cancer, restenosis and diabetic neuropathy |
| 04/11/2002 | US20020042091 Methods and compositions for screening modulators of lipid kinases |
| 04/11/2002 | US20020042089 Interleukin-5 specific recombinant antibodies |
| 04/11/2002 | US20020042087 Inducing preferential cell proliferation; obtain preferential cells, incubate with modulator, monitor cell sample for proliferation activity |
| 04/11/2002 | US20020042086 Activating vascular system propagation; for use in the treatment of repefusion injury and bronci defects |
| 04/11/2002 | US20020041888 Suspension containing microspheres; apoptosis inducing compound |
| 04/11/2002 | US20020041885 Inhibitor of immunoglobulin e antibody production |
| 04/11/2002 | US20020041884 Adenovirus formulations |
| 04/11/2002 | US20020041883 Topical applying |
| 04/11/2002 | US20020041873 Administering neutrotrophic factor inhibitor |
| 04/11/2002 | DE10049937A1 New sugar-modified amidine and guanidine compounds, useful as competitive inhibitors of serine protease, e.g. for treating thrombosis |
| 04/11/2002 | DE10046993A1 Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament Substituted Zimtsäureguanidide, processes for their preparation, their use as a medicament and they drug-containing |
| 04/11/2002 | CA2435976A1 Apoptosis inducers, caspase cascade activators and anticancer agents |
| 04/11/2002 | CA2426621A1 Drug resistance-associated gene and use thereof |
| 04/11/2002 | CA2425712A1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 04/11/2002 | CA2425266A1 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 04/11/2002 | CA2425264A1 Tumor proliferation inhibitors |
| 04/11/2002 | CA2425185A1 Benzimidazole and indole derivatives as crf receptor modulators |
| 04/11/2002 | CA2425169A1 Hematopoietin receptors hpr1 and hpr2 |
| 04/11/2002 | CA2425152A1 Highly expressible genes |
| 04/11/2002 | CA2425126A1 Lipid metabolism enzymes |
| 04/11/2002 | CA2425124A1 Selective anxiolytic therapeutic agents |
| 04/11/2002 | CA2425097A1 Benzamide compounds as apo b secretion inhibitors |
| 04/11/2002 | CA2424993A1 7-carboxy-flavone derivatives, preparation method and therapeutic use |
| 04/11/2002 | CA2424934A1 Association of the cb1 receptor antagonist and sibutramin, for treating obesity |
| 04/11/2002 | CA2424761A1 Method of treating cancer using dithiocarbamate derivatives |
| 04/11/2002 | CA2424749A1 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 04/11/2002 | CA2424730A1 Compositions and methods for the transport of biologically active agents across cellular barriers |
| 04/11/2002 | CA2424693A1 Induction of blood vessel formation by polynucleotides encoding sphingosine kinases |
| 04/11/2002 | CA2424623A1 Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| 04/11/2002 | CA2424622A1 Use of neuropeptide-y antagonists in treatment of alcoholism |
| 04/11/2002 | CA2424621A1 Combination particles for the treatment of asthma |
| 04/11/2002 | CA2424620A1 Inhalation particles incorporating a combination of two or more active ingredients |
| 04/11/2002 | CA2424555A1 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 04/11/2002 | CA2424296A1 Human anti-cd40 antibodies |
| 04/11/2002 | CA2424282A1 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist |
| 04/11/2002 | CA2424273A1 Citrullimycines, a process for their production and their use as pharmaceuticals |
| 04/11/2002 | CA2424222A1 Inhibitors of prenyl-protein transferase |
| 04/11/2002 | CA2424216A1 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/11/2002 | CA2423883A1 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors |
| 04/11/2002 | CA2423656A1 Methods and compositions for enhancing angiogenesis |
| 04/11/2002 | CA2423436A1 Methods and compositions for modulating t cell activation and uses thereof |
| 04/11/2002 | CA2423312A1 Condensed pyridoindole derivatives |
| 04/11/2002 | CA2421782A1 Quinoline and quinolinone derivatives as metabotropic glutamate receptor antagonists |
| 04/11/2002 | CA2421417A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/10/2002 | EP1195605A1 Methods and compositions for screening modulators of lipid kinases |
| 04/10/2002 | EP1195604A1 Methods and compositions for screening modulators of lipid kinases |
| 04/10/2002 | EP1195435A1 Truncated phosphodiesterase-7 polypeptides |
| 04/10/2002 | EP1195378A1 Pyridotriazines and pyridopyridazines |
| 04/10/2002 | EP1195165A1 Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate |
| 04/10/2002 | EP1195163A1 Serine protease inhibitor |
| 04/10/2002 | EP1195156A1 Use of an ericaceae extract in skin-ageing treatment |
| 04/10/2002 | EP1194595A1 Polymorphisms in the human hmg-coa reductase gene |
| 04/10/2002 | EP1194590A2 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
| 04/10/2002 | EP1194584A1 Method for producing oligopolysaccharides |
| 04/10/2002 | EP1194547A2 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 04/10/2002 | EP1194543A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 04/10/2002 | EP1194451A1 Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| 04/10/2002 | EP1194449A2 Inhibitors of memapsin 2 and use thereof |
| 04/10/2002 | EP1194443A1 Cysteinyl protease inhibitors |
| 04/10/2002 | EP1194441A2 Thiophene a2a receptor agonists |
| 04/10/2002 | EP1194439A1 Human eag2 |
| 04/10/2002 | EP1194436A1 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase |
| 04/10/2002 | EP1194429A1 Potassium channel openers |
| 04/10/2002 | EP1194425A1 Substituted benzimidazole |
| 04/10/2002 | EP1194411A1 Benzoylpyridazines |
| 04/10/2002 | EP1194404A1 Inhibitors of aspartyl protease |
| 04/10/2002 | EP1194173A1 X-ray guided drug delivery |
| 04/10/2002 | EP1194168A2 Methods and products for manipulating uncoupling protein expression |
| 04/10/2002 | EP1194164A1 Prion protein peptides and uses thereof |
| 04/10/2002 | EP1194157A1 D-form polypeptide which induces immune tolerance and methods of use |